Literature DB >> 21577117

Future cases as present controls to adjust for exposure trend bias in case-only studies.

Shirley Wang1, Crystal Linkletter, Malcolm Maclure, David Dore, Vincent Mor, Stephen Buka, Gregory A Wellenius.   

Abstract

Self-matched case-only studies (such as the case-crossover or self-controlled case-series method) control by design for time-invariant confounders (measured or unmeasured), but they do not control for confounders that vary with time. A bidirectional case-crossover design can be used to adjust for exposure-time trends. In pharmacoepidemiology, however, illness often influences future use of medications, making a bidirectional design problematic. Suissa's case-time-control design combines a case-crossover and case-control design, and adjusts for exposure-trend bias in the cases' self-controlled odds ratio by dividing that ratio by the corresponding self-controlled odds ratio in a concurrent matched control group. However, if not well matched, the control group may reintroduce selection bias. We propose a "case-case-time-control" that involves crossover analyses in cases and future-case controls. This person-time sampling strategy improves matching by restricting controls to future cases. We evaluate the proposed study design through simulations and analysis of a theoretically null relationship using Veterans Administration (VA) data. Simulation studies show that the case-case-time-control can adjust for exposure trends while controlling for time-invariant confounders. Use of an inappropriate control group left case-time-control analyses biased by exposure-time trends. When analyzing the relationship between vitamin exposure and stroke, using data on 3192 patients in the VA system, a case-crossover odds ratio of 1.5 (95% confidence interval = 1.3-1.7) was reduced to 1.1 (0.9-1.3) when divided by the concurrent exposure trend odds ratio (1.4) in matched future cases. This applied example demonstrates how our approach can adjust for exposure trends observed across time axes.

Entities:  

Mesh:

Year:  2011        PMID: 21577117      PMCID: PMC3110688          DOI: 10.1097/EDE.0b013e31821d09cd

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  11 in total

1.  Control for seasonal variation and time trend in case-crossover studies of acute effects of environmental exposures.

Authors:  T F Bateson; J Schwartz
Journal:  Epidemiology       Date:  1999-09       Impact factor: 4.822

2.  Risk set sampling for case-crossover designs.

Authors:  William Navidi; Eric Weinhandl
Journal:  Epidemiology       Date:  2002-01       Impact factor: 4.822

Review 3.  Control without separate controls: evaluation of vaccine safety using case-only methods.

Authors:  C P Farrington
Journal:  Vaccine       Date:  2004-05-07       Impact factor: 3.641

4.  Case-crossover analyses of air pollution exposure data: referent selection strategies and their implications for bias.

Authors:  Holly Janes; Lianne Sheppard; Thomas Lumley
Journal:  Epidemiology       Date:  2005-11       Impact factor: 4.822

5.  Tutorial in biostatistics: the self-controlled case series method.

Authors:  Heather J Whitaker; C Paddy Farrington; Bart Spiessens; Patrick Musonda
Journal:  Stat Med       Date:  2006-05-30       Impact factor: 2.373

6.  Case series analysis for censored, perturbed, or curtailed post-event exposures.

Authors:  C Paddy Farrington; Heather J Whitaker; Mounia N Hocine
Journal:  Biostatistics       Date:  2008-05-21       Impact factor: 5.899

7.  The case-crossover design: a method for studying transient effects on the risk of acute events.

Authors:  M Maclure
Journal:  Am J Epidemiol       Date:  1991-01-15       Impact factor: 4.897

8.  Bidirectional case-crossover designs for exposures with time trends.

Authors:  W Navidi
Journal:  Biometrics       Date:  1998-06       Impact factor: 2.571

9.  Case-crossover and case-time-control designs in birth defects epidemiology.

Authors:  Sonia Hernández-Díaz; Miguel A Hernán; Katie Meyer; Martha M Werler; Allen A Mitchell
Journal:  Am J Epidemiol       Date:  2003-08-15       Impact factor: 4.897

10.  The problem of "protopathic bias" in case-control studies.

Authors:  R I Horwitz; A R Feinstein
Journal:  Am J Med       Date:  1980-02       Impact factor: 4.965

View more
  13 in total

1.  Data Mining for Adverse Drug Events With a Propensity Score-matched Tree-based Scan Statistic.

Authors:  Shirley V Wang; Judith C Maro; Elande Baro; Rima Izem; Inna Dashevsky; James R Rogers; Michael Nguyen; Joshua J Gagne; Elisabetta Patorno; Krista F Huybrechts; Jacqueline M Major; Esther Zhou; Megan Reidy; Austin Cosgrove; Sebastian Schneeweiss; Martin Kulldorff
Journal:  Epidemiology       Date:  2018-11       Impact factor: 4.822

2.  "First-wave" bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs.

Authors:  Shirley V Wang; Sebastian Schneeweiss; Malcolm Maclure; Joshua J Gagne
Journal:  Am J Epidemiol       Date:  2014-08-01       Impact factor: 4.897

3.  Patterns of β-blocker initiation in patients undergoing intermediate to high-risk noncardiac surgery.

Authors:  Elisabetta Patorno; Shirley V Wang; Sebastian Schneeweiss; Jun Liu; Brian T Bateman
Journal:  Am Heart J       Date:  2015-07-26       Impact factor: 4.749

4.  Case-crossover studies of therapeutics: design approaches to addressing time-varying prognosis in elderly populations.

Authors:  Shirley V Wang; Joshua J Gagne; Robert J Glynn; Sebastian Schneeweiss
Journal:  Epidemiology       Date:  2013-05       Impact factor: 4.822

5.  Bias in case-crossover studies of medications due to persistent use: A simulation study.

Authors:  Katsiaryna Bykov; Shirley V Wang; Jesper Hallas; Anton Pottegård; Malcolm Maclure; Joshua J Gagne
Journal:  Pharmacoepidemiol Drug Saf       Date:  2020-06-16       Impact factor: 2.890

Review 6.  Analytic and Data Sharing Options in Real-World Multidatabase Studies of Comparative Effectiveness and Safety of Medical Products.

Authors:  Sengwee Toh
Journal:  Clin Pharmacol Ther       Date:  2020-01-24       Impact factor: 6.875

7.  Initiation patterns of statin therapy among adult patients undergoing intermediate to high-risk non-cardiac surgery.

Authors:  Elisabetta Patorno; Shirley V Wang; Sebastian Schneeweiss; Jun Liu; Brian T Bateman
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-10-22       Impact factor: 2.890

8.  Population-based analysis of non-steroidal anti-inflammatory drug use among children in four European countries in the SOS project: what size of data platforms and which study designs do we need to assess safety issues?

Authors:  Vera E Valkhoff; René Schade; Geert W 't Jong; Silvana Romio; Martijn J Schuemie; Andrea Arfe; Edeltraut Garbe; Ron Herings; Silvia Lucchi; Gino Picelli; Tania Schink; Huub Straatman; Marco Villa; Ernst J Kuipers; Miriam C J M Sturkenboom
Journal:  BMC Pediatr       Date:  2013-11-19       Impact factor: 2.125

9.  A mixed method to evaluate burden of malaria due to flooding and waterlogging in Mengcheng County, China: a case study.

Authors:  Guoyong Ding; Lu Gao; Xuewen Li; Maigeng Zhou; Qiyong Liu; Hongyan Ren; Baofa Jiang
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

Review 10.  Medication safety research by observational study design.

Authors:  Kim S J Lao; Celine S L Chui; Kenneth K C Man; Wallis C Y Lau; Esther W Chan; Ian C K Wong
Journal:  Int J Clin Pharm       Date:  2016-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.